Predictive Value of FDG-TEP During Exclusive Chemo-Radiotherapy (CRT) in Patients With Oesophageal Carcinoma Cancer on the One-Year Survival (RTEP3)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Oesophageal Cancer
Both
Oesophageal Cancer
Trial Information
Predictive Value of FDG-TEP During Exclusive Chemo-Radiotherapy (CRT) in Patients With Oesophageal Carcinoma Cancer on the One-Year Survival (RTEP3)
Inclusion Criteria:
- Carcinoma épidermoïde of the oesophagus histologically proved, UICC Stage II B, III
or IVa (TNM on 2002)
- Decision of treatment by radio concomitant chemotherapy (radiotherapy in classic
spreading of 50Gy associated with a platinum chemotherapy.
Exclusion Criteria:
- Presence of a second evolutionary cancer in the previous three years
- index of performance OMS > 2
- Patients badly balanced diabetics
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Principal Investigator
VERA Pierre, MD phD
Investigator Role:
Principal Investigator
Investigator Affiliation:
CHBecquerel
Authority:
France: Institutional Ethical Committee
Study ID:
CHB08-02
NCT ID:
NCT00934505
Start Date:
May 2009
Completion Date:
April 2014
Related Keywords:
- Oesophageal Cancer
- Positron-Emission Tomography
- PET Scan
- FDG
- oesophageal cancer
- chemo-Radiation Oncology
- SUV
- Carcinoma
- Esophageal Diseases
- Esophageal Neoplasms
Name | Location |
|---|
